is...wondering why God loves us so much?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$BORN wth?
GM Bounce ! :)
GOOD MORNING SSS!
HAHA!! Nice Parallel, when does the tea party come in play :)
thanks for all your insight EI!
this was a nutty ticker.
Hi EI - What does it mean :)
:)
LOL :) Damn than DD!!
Conference Call 4 pm tomorrow in regards to Phase IIb Positive results (News this AM)
ARDM Bounce
hhahahahahahahaha - i don't know how to dabka lol
sigh - you're all over.
If the glove don't fit - you must acquit.
Im late lol
LOL! omg!
Agreed EH!! :)
fine - i like your link better :)
Reason? Link posted
Possible Cause
Blue was only reply to me as i see it so clearly!
touche!
Z - Share count Check :)
Treasury plans sale of 1.5 billion Citi shares
8:42a ET October 19, 2010 (MarketWatch)
WASHINGTON (MarketWatch) -- The Treasury Department said it's entered into its fourth pre-arranged trading plan to sell Citigroup common stock, as Morgan Stanley will sell 1.5 billion shares as Treasury's sales agent. The sale of 1.5 billion additional shares of Citigroup common stock would bring Treasury's holdings of Citigroup common stock to approximately 7% of total shares outstanding, down from a high of approximately 27%. It would also mean that Treasury had disposed of nearly three-quarters of its original 7.7 billion share common stock stake in Citigroup. To date, taxpayers have received a total of $41.6 billion in revenue from the $45 billion TARP investment through repayments, dividends and interest, the sale of common stock, and the sale of other securities, Treasury said.
i lost track of what's left from their selling for this yr?
GM BLUE!
Rexahn Pharmaceuticals Publishes New Data on Anti-Cancer Isoquinolinamine Derivatives
8:00a ET October 19, 2010 (Business Wire)
Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced the publication of new preclinical data on the development of 3-aryl-1-isoquinolinamines in the European Journal & Medicinal Chemistry [45:5493-5497, 2010].
In the study, various substituted 3-aryl-1-isoquinolinamine derivatives were shown to have excellent cytotoxicity against eight different human cancer cells (breast, prostate, colon, ovary, kidney, pancreas, glioblastoma, melanoma). These derivatives were synthesized and evaluated through the constructed QSAR (quantitative structure-activity relationship) model and in vitro cell studies. QSAR technique is used in drug design and virtual screening to find lead compounds. The cytotoxic activities of new designed compounds are calculated using the constructed QSAR model and compared with actual cytotoxic data using the synthesized compounds.
"In this second published study, we further establish that isoquinolinamine derivatives, such as our anti-cancer compound RX-8243 - a new chemical entity - are potent anti-cancer compounds that have the potential to be developed into chemotherapeutic agents," said Rick Soni, President of Rexahn.
Last month Rexahn announced the publication of new preclinical data in Bioorganic & Medicinal Chemistry Letters demonstrating that RX-8243, an isoquinolinamine analogue, significantly inhibits the growth of human cancer cells, including paclitaxel (Taxol(R)) resistant HCT-15 human colorectal cancer cells and the growth of tumor in in vivo model of nude mice injected with paclitaxel-resistant HCT-15 human colorectal cancer cells.
About Rexahn Pharmaceuticals, Inc.
Rexahn Pharmaceuticals is a clinical stage pharmaceutical company dedicated to developing and commercializing best in class and market leading therapeutics for cancer, CNS disorders, sexual dysfunction and other unmet medical needs. Rexahn currently has three drug candidates in Phase II clinical trials, Archexin(R), Serdaxin(R), and Zoraxel(TM) - all potential best in class therapeutics - and a robust pipeline of preclinical compounds to treat multiple cancers and CNS disorders. Rexahn also operates key R&D programs of nano-medicines, 3D-GOLD, and TIMES drug discovery platforms. For more information, please visit www.rexahn.com.
Safe Harbor
To the extent any statements made in this press release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about Rexahn's plans, objectives, expectations and intentions with respect to future operations and products and other statements identified by words such as "will," "potential," "could," "can," "believe," "intends," "continue," "plans," "expects," "anticipates," "estimates," "may," other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause Rexahn's actual results to be materially different than those expressed in or implied by Rexahn's forward-looking statements. For Rexahn, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of Rexahn's licensees or sublicensees; the success of clinical testing; and Rexahn's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect Rexahn's actual results are described in Rexahn's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. Rexahn undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
SOURCE: Rexahn Pharmaceuticals, Inc.
Rexahn Pharmaceuticals, Inc.
Investor Relations
Stern Investor Relations, Inc.
Stephanie Ascher, 212-362-1200
stephanie@sternir.com
or
Base Pair Communications
Constantine Theodoropulos, 617-401-3116
constantine@basepaircomm.com
GM Z !
i think they expected 580K?
GM Alien :)
GM FED !
GM YAK!
GM SSS :)
GS tops Earnings
BAC $7.4B loss (loss widens)
never ending rinse/repeat - and we all have short memory as well as short sightedness - :(
so sad
Z - are you referring to Prolia? or another one? (ie prolia already approved)
GM TM
Long awaited for RBCN
gm Fed